Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
30
30 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IBI362Phase 38 trials
Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- RAY1225Phase 35 trials
Guangdong Raynovent Biotech Co., Ltd · Obesity, T2DM, T2DM (Type 2 Diabetes Mellitus)
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- IBI343Arcotatug TavatecanPhase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · CLDN18.2 Positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma
- IBI311Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED
- IBI354Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal
- LimertinibPhase 33 trials
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
- Oteracil Potassiumgimeracil], S-1 [TegafurPhase 33 trials
AstraZeneca · Biliary Tract Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasms of Digestive Organs
- TigulixostatIBI128, LC350189Phase 33 trials
Innovent Biologics Technology Limited (Shanghai R&D Center) · Gout, Hyperuricemia, Gout Flare
- IBI112Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriasis
- IBI302Phase 32 trials
Innovent Biologics (Suzhou) Co. Ltd. · Neovascular Age-related Macular Degeneration, Diabetic Macular Oedema
- IBI310Phase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- ZSP1273Phase 32 trials
Guangdong Raynovent Biotech Co., Ltd · Influenza A, Influenza a
- IBI3027Phase 31 trial
Innovent Biologics (Suzhou) Co. Ltd. · Atopic Dermatitis
- IBI306Phase 31 trial
Innovent Biologics (Suzhou) Co. Ltd. · Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
- IBI129Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Solid Tumor
- IBI133Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors
- IBI3002Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Atopic Dermatitis
- IBI3005Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Solid Tumor
- IBI3014Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Unresectable Locally Advanced or Metastatic Solid Tumors
- IBI3016Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Hypertension
- IBI305Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
- IBI334Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Advanced Solid Tumors
- IBI355Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Sjögren's Disease
- ZSP1601Phase 21 trial
Guangdong Raynovent Biotech Co., Ltd · Nonalcoholic Steatohepatitis (NASH)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.